|
| Main | | |
| Brand Name | Symbicort |
| Mechanism | Combination LABA (formoterol is also fast acting 1-2 minutes) and corticosteroid |
| Administration | Inhaled - SMART variable dosing filed - allows patient to use 1-4 inhalations bid to prevent attacks - no second inhaler needed (second inhaler with salbutamol needed) |
| | Turbuhaler device. Also developed as an MDI. |
| Indication | Asthma, COPD |
| Economics | 100%, jointly promoting with Astellas in Japan. |
| Competition | Advair. Symbicort can be used to prevent as well as treat acute attacks. |
| | Symbicort's formoterol has an onset of action of 5 minutes vs sameterol's 30-60 minutes. |
| Timeline | Launched 5/18/2007. |
| Clinical Trials | COSMOS - significant decrease in asthmatic exacerbations in patients using Symbicort SMART compared to Advair - 30% reduction |
| | COMPASS - Symbicort reduced exacerbations 39% more than Advair and 28% more than fixed-dose Symbicort |
| | SMILE |
| | 4 head-to-head trials of Symbicort vs Advair |
| | SUND showed patient-controlled variability of dosing reduced exacerbations by 40% vs Advair |